Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-011 in Osteolytic Lesions of Multiple Myeloma
NCT00747123Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2008
- Primary completion
- Aug 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sotatercept in multiple myeloma (MM), sponsored by Celgene Corporation. Started Sep 2008; status: completed.
02
Drugs
sotatercept
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00747123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00747123.